vs
Side-by-side financial comparison of Abbott Laboratories (ABT) and Adagene Inc. (ADAG). Click either name above to swap in a different company.
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Adagene Inc. is a global clinical-stage biotechnology company specializing in the research, development, and commercialization of innovative antibody-based cancer immunotherapies. Leveraging its proprietary next-generation antibody technology platforms, it develops targeted oncology treatments for patients across global markets, with core R&D bases in China and clinical programs covering North America, Asia, and Europe.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.5B | — | ||
| Q3 25 | $11.4B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.4B | — | ||
| Q4 24 | $11.0B | — | ||
| Q3 24 | $10.6B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $10.0B | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $9.2B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 55.2% | — |
| Q4 25 | 19.6% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 18.4% | — | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 17.5% | — | ||
| Q2 24 | 16.1% | — | ||
| Q1 24 | 13.9% | — |
| Q4 25 | 15.5% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 15.5% | — | ||
| Q2 24 | 12.5% | — | ||
| Q1 24 | 12.3% | — |
| Q4 25 | $1.01 | — | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $1.01 | — | ||
| Q1 25 | $0.76 | — | ||
| Q4 24 | $5.26 | — | ||
| Q3 24 | $0.94 | — | ||
| Q2 24 | $0.74 | — | ||
| Q1 24 | $0.70 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
